Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial 达格列净治疗接受二甲双胍治疗失败的亚洲2型糖尿病患者的疗效和安全性:一项随机对照研究
Dapagliflozin, a highly selective sodium–glucose cotransporter 2 inhibitor, reduces hyperglycemia, body weight, and blood pressure in patients with type 2 diabetes (T2D).